Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke
CEO and Managing Director, Steven Yatomi-Clarke, held an investor briefing with Reach Markets where he discussed the data from their Phase 1b trial, how they are well poised to progress toward commercialisation and how their other assets are progressing.
During the briefing, Steven discussed:
- Why the data from the PTX-100 Phase 1b trial is so promising, and why Prescient is on the cusp of a significant inflection point.
- The opportunities available for an effective therapy in T-cell lymphomas – a disease of unmet need.
- How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths.
- How Prescient’s $18m cash position allows them to go deep into a Phase 2 trial.
Recorded on 9th April 2024 (AEDT)
Featured Speaker
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development.
Previously, Steven had a distinguished career as an investment banker specialising in the life sciences sector, where he was consistently one of the country’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments. In particular, Steven leveraged his combined backgrounds in science and finance to identify undervalued and unlikely opportunities and structure deals for the mutual benefit of companies and investors.
Steven holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, both from the University of Melbourne. He has been a collaborator on various immunotherapy research projects.
